Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12270231 | 0.88 | PCSK9 (0.52) | PCSK9ATMPTGS2PTGS1RAB9A | |
| SCHEMBL28615315 | 0.88 | PCSK9 (0.44) | PCSK9ATMPTGS2PTGS1RAB9A | |
| Formamide SCHEMBL28739639 | 0.88 | ATM (0.52) | PCSK9ATMPTGS2PTGS1RAB9A | |
| SCHEMBL25611797 | 0.86 | NOTUM (0.46) | PCSK9PTGS2PTGS1RAB9ANPC1 | |
| SCHEMBL27936097 | 0.86 | PTGS2 (0.62) | PCSK9ATMPTGS2PTGS1RAB9A | |
| SCHEMBL6283123 | 0.86 | MMP3 (0.46) | PCSK9ATMPTGS2PTGS1RAB9A | |
| SCHEMBL15591146 | 0.82 | PTGS2 (0.41) | PCSK9ATMPTGS2PTGS1RAB9A | |
| SCHEMBL6286504 | 0.81 | RAB9A (0.50) | ATMPTGS2RAB9ANPC1ALDH1A1 | |
| SCHEMBL28805488 | 0.81 | TAAR1 (0.52) | PCSK9ATMPTGS2PTGS1NPC1 | |
| SCHEMBL13045141 | 0.80 | PCSK9 (0.49) | PCSK9PTGS2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758414-B1 | RUTHENIUM CONTAINING HYDROSILYLATION CATALYSTS AND COMPOSITIONS CONTAINING THE CATALYSTS | DOW SILICONES CORP (US) | 2018-11-21 | — | — | EP | claimed |
| CN-107573273-A | A kind of preparation method of three substitution, 3 cyanopyrrole analog derivatives | 浙江大学 | 2018-01-12 | — | — | CN | claimed |
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8247423-B2 | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS INC. (US) | 2012-03-01 | — | — | US | claimed |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | claimed |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | TRAGARA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | claimed |
| US-20110301209-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | claimed |
| JP-2011506277-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2175722-A2 | PATIENT SELECTION AND THERAPEUTIC METHODS USING MARKERS OF PROSTAGLANDIN METABOLISM | Tragara Pharmaceuticals, Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| EP-2170062-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | Tragara Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009070547-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | claimed |
| WO-2009070546-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | claimed |
| WO-2009042612-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2009042613-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR [ERBB1] AND HER-2 [ERBB2] | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2009042618-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2009009778-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| WO-2009009776-A2 | PATIENT SELECTION AND THERAPEUTIC METHODS USING MARKERS OF PROSTAGLANDIN METABOLISM | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084281-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | PCSK9 511/4885ATM 1259/4885PTGS2 565/4885 |
| US-20090017024-A1 | Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders | TP53, VHL, TSG101 | PCSK9 511/4885ATM 1259/4885PTGS2 565/4885 |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | ERBB2, EGFR, ERBB3 | PCSK9 2479/4885ATM 2229/4885PTGS2 11/4885 |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | PTGER2, PTGES2, PTGS2 | PCSK9 1382/4885ATM 1790/4885PTGS2 3/4885 |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | PTGS2, PTGES2, PTGER2 | PCSK9 2211/4885ATM 2994/4885PTGS2 1/4885 |
| US-20120052061-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | ERBB2, PTGER2, PTGS2 | PCSK9 2245/4885ATM 1781/4885PTGS2 3/4885 |
| US-20110301209-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TP53, VHL, TSG101 | PCSK9 511/4885ATM 1259/4885PTGS2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.